Noble Life Sciences Animal Facility Awarded Full AAALAC Accreditation
News Nov 01, 2013
Noble Life Sciences has announced that its animal facility was awarded full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International).
AAALAC assessment and accreditation programs are designed to recognize organizations that demonstrate excellence in animal care and use.
Organizations volunteer to participate in AAALAC's program in addition to complying with local, state and federal laws that regulate use of animals in research.
Accreditation was awarded following submission of a detailed program description and an in-depth review of the program and facility during an on-site visit by AAALAC representatives.
In addition, Noble is currently licensed by the United States Department Of Agriculture (USDA) and meets the assurance requirements of the National Institutes of Health’s Office of Laboratory Animal Welfare (OLAW).
Alain Cappeluti, President of Noble Life Sciences, commented: “We are pleased to receive unanimous approval from AAALAC International for full accreditation with no additional recommendations for improvement. Accreditation recognizes our commitment to exceed international standards with the highest level of animal care and research practices. It also demonstrates our dedication to providing our clients with superior resources and services to advance their preclinical research programs.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE